← back to search

Jörg Huwyler

Swiss Centre for Applied Human Toxicology · CH
Area of research
Molecular Biology · Oncology
Research interest
Research interests include Protein purification and stability, Drug Transport and Resistance Mechanisms, RNA Interference and Gene Delivery, and Nanoparticle-Based Drug Delivery.
h-index
63
citations
15,702
works
327
NIH funding
primary concept
Chemistry
email

Recent publications

Nano Plasma Membrane Vesicle-Lipid Nanoparticle Hybrids for Enhanced Gene Delivery and Expression.
2025cited by 9position: contributordoi
Zebrafish as a model to assess the neurotoxic potential of propylene glycol ethers.
2025cited by 7position: contributordoi
Capillary-Based Physicochemical Characterization of Lipid Nanoparticles.
2025cited by 1position: contributordoi
Drug loading mechanism of hollow hydroxyapatite microcapsules.
2025cited by 0position: contributordoi
Corrigendum to "Comparison of ionizable lipids for lipid nanoparticle mediated DNA delivery" [European Journal of Pharmaceutical Sciences 203 (2024), 106898].
2025cited by 0position: contributordoi
Refining pain management in mice by comparing multimodal analgesia and NSAID monotherapy for neurosurgical procedures
Scientific Reports 2024cited by 13position: middledoi
Lipid conjugate dissociation analysis improves the in vivo understanding of lipid-based nanomedicine.
2024cited by 8position: contributordoi
Refining pain management in mice by comparing multimodal analgesia and NSAID monotherapy for neurosurgical procedures.
2024cited by 7position: contributordoi
Novel Strategy to Assess the Neurotoxicity of Organic Solvents Such as Glycol Ethers: Protocol for Combining In Vitro and In Silico Methods With Human-Controlled Exposure Experiments.
2024cited by 6position: contributordoi
Comparison of ionizable lipids for lipid nanoparticle mediated DNA delivery.
2024cited by 5position: contributordoi
Characterization of Silicone from Closed System Transfer Devices and its Migration into Pharmaceutical Drug Products.
2024cited by 5position: contributordoi
Characterization of Freezing Processes in Drug Substance Bottles by Ice Core Sampling.
2024cited by 4position: contributordoi
A Survey on Handling and Administration of Therapeutic Protein Products in German and Swiss Hospitals.
2024cited by 3position: contributordoi
Novel Patient-Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use.
2024cited by 3position: contributordoi
Aluminum and ABC transporter activity.
2024cited by 2position: contributordoi
Directional freezing and thawing of biologics in drug substance bottles.
2024cited by 1position: contributordoi
Optimization of Methodologies to Study Freeze/Thaw Processes in Drug Substance Bottles.
2024cited by 1position: contributordoi
Impact of the Design of Different Infusion Containers on the Dosing Accuracy of a Therapeutic Drug Product.
2024cited by 0position: contributordoi
Pharmacometrics to Evaluate Dosing of the Patient-Friendly Ivermectin CHILD-IVITAB in Children ≥ 15 kg and <15 kg.
2024cited by 0position: contributordoi
Polyethylenimine (PEI) in gene therapy: Current status and clinical applications.
2023cited by 160position: contributordoi
The processes behind drug loading and release in porous drug delivery systems.
2023cited by 41position: contributordoi
A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models
Scientific Reports 2023cited by 21position: middledoi
Calcium Phosphate Microcapsules as Multifunctional Drug Delivery Devices
Advanced Functional Materials 2023cited by 17position: contributordoi
High efficiency preparation of monodisperse plasma membrane derived extracellular vesicles for therapeutic applications.
2023cited by 15position: contributordoi
Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children.
2023cited by 14position: contributordoi
A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models.
2023cited by 12position: contributordoi
Core-Shell Structured Chitosan-Polyethylenimine Nanoparticles for Gene Delivery: Improved Stability, Cellular Uptake, and Transfection Efficiency.
2023cited by 9position: contributordoi
Zebrafish (Danio rerio) larvae as a predictive model to study gentamicin-induced structural alterations of the kidney.
2023cited by 7position: contributordoi
Comparison of cell viability methods for human mesenchymal/stromal stem cells and human A549 lung carcinoma cells after freeze-thaw stress.
2023cited by 4position: contributordoi
Design and Characterization of Mutated Variants of the Oncotoxic Parvoviral Protein NS1
Viruses 2023cited by 3position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

· 41 papers (2019–2025)Maxim Puchkov · MDPI7 papers (2019–2025)Dominik Witzigmann · American Chemical Society5 papers (2019–2021)Manuel Haschke · University of Bern4 papers (2019–2021)Jonas Kost · University of Basel4 papers (2023–2025)Michael Buettcher · University of Lucerne3 papers (2023–2024)Christian M. Schlepütz · Swiss Federal Laboratories for Materials Science and Technology3 papers (2020–2022)Pascal Detampel · University of Basel3 papers (2021–2025)Hanns-Christian Mahler · Mat-Tec (Switzerland)3 papers (2024–2024)Marc Pfister · University Hospital of Basel3 papers (2023–2024)Robert Klopfleisch · Freie Universität Berlin3 papers (2022–2023)Dominik Witzigmann · FPInnovations3 papers (2014–2021)Bert Müller · University Hospital of Basel3 papers (2020–2023)Hélène Paschoud · University of Lausanne2 papers (2023–2024)Max Löhning · Freie Universität Berlin2 papers (2022–2023)Jens Casper · University of Basel2 papers (2021–2023)Ramya Deepthi Puligilla · University of Basel2 papers (2023–2024)Elena Reale · Nestlé (Switzerland)2 papers (2023–2024)David Pamies · National Institute of Environmental Health Sciences2 papers (2023–2024)Laura Suter-Dick · Biotechnet Switzerland2 papers (2023–2024)